JPY 3,000.00
-108.00 (-3.47%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 2503.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluate the Effects of Citicoline on Mood in Healthy AdultsNCT07089238Total Mood Disturbance (TMD) score on the Profile of Mood States second eddition-Adult short (POMS2)Randomized · Triple-masked · Health services research | Not applicable | Recruiting | Dietary supplement: Citicoline, Placebo | Healthy | 90 | 2026-03-31 | 2025-09-02 |
| Evaluate the Effects of Citicoline on Cognitive Performance in Healthy AdultsNCT06906848To evaluate the effect of the Test Product (TP) on cognitive performance compared to a placebo after 12 weeks using the Psychomotor Vigilance Test (PVT)Randomized · Triple-masked · Health services research | Not applicable | Completed | Dietary supplement: Placebo, Cognizin® | Healthy, Cognitive Performance | 90 | 2025-05-31actual | 2025-07-09 |
| Cognitive Effects of Citicoline on Attention in Healthy Mean and WomenNCT04967157Composite score calculated based on scores from the Computerized Mental Performance Assessment System (COMPASS, Northumbria University, Newcastle upon Tyne, UK) that measure cognitive assessmentRandomized · Triple-masked · Basic science | Not applicable | Completed | Dietary supplement: Placebo supplement, Citicoline supplement | Healthy | 148 | 2022-08-31actual | 2025-04-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19